Literature DB >> 28983950

Epidemiology and comorbidities of patients with chronic urticaria in Korea: A nationwide population-based study.

Bo Ri Kim1, Seungkeol Yang1, Jee Woong Choi1, Chong Won Choi1, Sang Woong Youn1.   

Abstract

Few population-based studies have focused on the epidemiology and comorbidities of chronic urticaria (CU) or chronic spontaneous urticaria (CSU). The objective of this study was to obtain information on the epidemiology and comorbidities associated with CU and CSU in Korea. We conducted a cross-sectional analysis using a national health insurance database. An algorithm based on the International Classification of Diseases, 10th revision, was used for the identification of patients with CU and CSU, and an age-sex adjusted logistic regression model was used to assess the risk of comorbidities in these patients. The average annual prevalence rates of CU and CSU during the 4-year period between 2010 and 2013 were 3.08% and 1.40%, respectively. The prevalence rates of CU and CSU were higher in women than men (1:1.39 and 1:1.34, respectively) and peaked at 0-9 and 70-79 years, respectively. After adjustment for age and sex, the patients with CU and CSU were found to have a significantly higher prevalence rate of CU/CSU-related diseases, compared with those without CU (mean adjusted odds ratio, 8.46; 95% confidence interval, 8.10-8.83). Allergic rhinitis, drug allergies, asthma, thyroid diseases and cancers were the most common comorbidities. Stomach, thyroid, liver and prostate cancers were the most prevalent cancers. This study provides large epidemiological data on the prevalence rates of CU and CSU, and their comorbidities, in Korea. Patients with CU and CSU impose a higher burden, in terms of specific comorbidities, than those without CU.
© 2017 Japanese Dermatological Association.

Entities:  

Keywords:  chronic spontaneous urticaria; chronic urticaria; comorbidity; epidemiology; national health programs

Mesh:

Year:  2017        PMID: 28983950     DOI: 10.1111/1346-8138.14075

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  12 in total

Review 1.  Urticaria.

Authors:  Pavel Kolkhir; Ana M Giménez-Arnau; Kanokvalai Kulthanan; Jonny Peter; Martin Metz; Marcus Maurer
Journal:  Nat Rev Dis Primers       Date:  2022-09-15       Impact factor: 65.038

2.  Clinical Features of Urticaria: Results From a Hospital-Based Multicenter Study in China.

Authors:  Xin Wang; Li-Juan Liu; Lin-Feng Li; Xiao-Dong Shi; Yi-Wei Shen
Journal:  Front Med (Lausanne)       Date:  2022-06-09

Review 3.  The KAAACI/KDA Evidence-Based Practice Guidelines for Chronic Spontaneous Urticaria in Korean Adults and Children: Part 1. Definition, Methodology and First-line Management.

Authors:  Woo Jung Song; Mira Choi; Dong Hun Lee; Jae Woo Kwon; Gun Woo Kim; Myung Hwa Kim; Mi Ae Kim; Min Hye Kim; Byung Keun Kim; Sujeong Kim; Joung Soo Kim; Jung Eun Kim; Ju Young Kim; Joo Hee Kim; Hyun Jung Kim; Hye One Kim; Hyo Bin Kim; Joo Young Roh; Kyung Hee Park; Kui Young Park; Han Ki Park; Hyunsun Park; Jung Min Bae; Ji Yeon Byun; Dae Jin Song; Young Min Ahn; Seung Eun Lee; Young Bok Lee; Joong Sun Lee; Ji Hyun Lee; Kyung Hwan Lim; Young Min Ye; Yoon Seok Chang; You Hoon Jeon; Jiehyun Jeon; Mihn Sook Jue; Sun Hee Choi; Jeong Hee Choi; Gyu Young Hur; Young Min Park; Dae Hyun Lim; Sang Woong Youn
Journal:  Allergy Asthma Immunol Res       Date:  2020-07       Impact factor: 5.764

Review 4.  Chronic Urticaria: An Overview of Treatment and Recent Patents.

Authors:  Kam L Hon; Alexander K C Leung; Wing G G Ng; Steven K Loo
Journal:  Recent Pat Inflamm Allergy Drug Discov       Date:  2019

5.  Clinical characteristics and management of chronic spontaneous urticaria in patients refractory to H1-Antihistamines in Asia, Middle-East and Africa: Results from the AWARE-AMAC study.

Authors:  Chia-Yu Chu; Anwar Al Hammadi; Nancy Agmon-Levin; Nilgun Atakan; Assem Farag; Rand K Arnaout; Suretha Kannenberg; Kanokvalai Kulthanan; Asmara Mubarak; Fares Zaitoun; Susanne Crowe; Sigrid Malfait; Kathryn Cooke; Elise L Dekker
Journal:  World Allergy Organ J       Date:  2020-04-30       Impact factor: 4.084

6.  Omalizumab usage in chronic urticaria and atopic dermatitis: data from South-East province of Turkey.

Authors:  Hülya Nazik; Mehmet Kamil Mülayim; Perihan Öztürk
Journal:  Postepy Dermatol Alergol       Date:  2019-12-30       Impact factor: 1.837

7.  Risk of comorbidities in patients diagnosed with chronic urticaria: A nationwide registry-study.

Authors:  Misbah Noshela Ghazanfar; Line Kibsgaard; Simon Francis Thomsen; Christian Vestergaard
Journal:  World Allergy Organ J       Date:  2020-01-25       Impact factor: 4.084

Review 8.  Expert consensus on the use of omalizumab in chronic urticaria in China.

Authors:  Zuotao Zhao; Tao Cai; Hong Chen; Liuqing Chen; Yudi Chen; Xiang Gao; Xinghua Gao; Songmei Geng; Yinshi Guo; Fei Hao; Guodong Hao; Yan Hu; Hongzhong Jin; Zhehu Jin; Chengxin Li; Haili Li; Jie Li; Yanming Li; Yunsheng Liang; Guanghui Liu; Qiang Liu; Hai Long; Lin Ma; Yuanyuan Shang; Yuxin Song; Zhiqiang Song; Xiangyang Su; Haijing Sui; Qing Sun; Yuemei Sun; Jianping Tang; Xunliang Tong; Huiying Wang; Gang Wang; Lianglu Wang; Siqin Wang; Li Xiang; Ting Xiao; Zhiqiang Xie; Leping Ye; Yongmei Yu; Chunlei Zhang; Litao Zhang; Shuchen Zhang; Rui Zheng; Lili Zhi; Wei Zhou; Ying Zou; Marcus Maurer
Journal:  World Allergy Organ J       Date:  2021-12-05       Impact factor: 4.084

Review 9.  The challenges of chronic urticaria part 1: Epidemiology, immunopathogenesis, comorbidities, quality of life, and management.

Authors:  Mario Sánchez-Borges; Ignacio J Ansotegui; Ilaria Baiardini; Jonathan Bernstein; Giorgio Walter Canonica; Motohiro Ebisawa; Maximiliano Gomez; Sandra Nora Gonzalez-Diaz; Bryan Martin; Mário Morais-Almeida; Jose Antonio Ortega Martell
Journal:  World Allergy Organ J       Date:  2021-06-01       Impact factor: 4.084

10.  Investigation of self-reported chronic urticaria among adults in grasslands of northern China.

Authors:  Yan-Lei Chen; Hai-Yun Shi; Ting-Ting Ma; Xue-Yan Wang
Journal:  Medicine (Baltimore)       Date:  2020-11-20       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.